Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe

INTRODUCTION: Additional risk minimisation measures (aRMMs) may be required to minimise important risks of medicines. aRMMs may be required at the time of authorisation, but may also be introduced or discontinued during the product life cycle as new safety information arises. The aim of this study i...

Descripción completa

Detalles Bibliográficos
Autores principales: Francisca, Reynold D. C., Baba, Emna, Hoeve, Christina E., Zomerdijk, Inge M., Sturkenboom, Miriam C. J. M., Straus, Sabine M. J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813721/
https://www.ncbi.nlm.nih.gov/pubmed/33000427
http://dx.doi.org/10.1007/s40264-020-00993-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813721/
https://www.ncbi.nlm.nih.gov/pubmed/33000427
http://dx.doi.org/10.1007/s40264-020-00993-6

Ejemplares similares